QIAGEN N.V.’s QGEN long-term business strategy focuses on forming partnerships for the development, commercialization, marketing and distribution of existing and future products. The company ...

EPS; adj. operating income margin improves 1.8 percentage points to 28.7% QIAGEN expects the solid growth pace in H2 2024 to continue in 2025. Net sales are expected to rise about 4% CER (and core ...

QIAGEN announced earlier in January plans for the repurchase, which comes after QIAGEN returned approximately $300 million to shareholders in early 2024 also through a synthetic share repurchase.

This new repurchase comes after QIAGEN returned approximately $300 million to shareholders in early 2024 through a synthetic share repurchase. Together, these two programs represent $600 million ...

The value of Qiagen's common shares will be increased through a transfer from the share premium reserve to allow for the capital repayment to shareholders, followed by a reverse stock split to ...

Background Recurrent preimplantation embryo developmental arrest (RPEA) is the most common phenotype in assisted reproductive technology treatment failure associated with identified genetic ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.